Seasoned drug developers and top KOLs driving VANADIS® through Phase 1B/2A and into successful pharma partnerships

  • Purpose‑Built, Partner‑Ready

    Led by seasoned biotech executives and renowned cardiovascular advisors, CFM Pharma’s team combines hands‑on clinical‑trial expertise with a robust licensing track record—providing the capabilities needed to steer VANADIS® through Phase 1B/2A trials and secure early‑stage pharmaceutical partnerships.

  • Drs. Ing. Lekhram Changoer – CEO

    Lekhram Changoer is a seasoned biotech entrepreneur who has co‑founded multiple IP‑driven pharmaceutical companies and guided them from preclinical research all the way to product licensing. Over the past 20 years, he has built deep expertise in launching clinical trials, steering R&D pipelines, crafting strategic business plans, securing licensing agreements, and forging partnerships with pharma firms, CROs, GMP manufacturers, and academic institutions.

    • MSc Organic Chemistry; BSc Analytical & Organic Chemistry

    • 20+ years in pharma R&D, clinical development & commercialization

    • Co‑founded three IP‑based biotechs; led product planning, global launches & licensing

  • Ir. David Havenaar – Legal & Finance Director

    David is an international executive with more than three decades of management experience across industry, technology and life sciences. Working closely with the CEO, he helps shape CFM Pharma’s strategy, legal and financial framework, funding activities and research partnerships, supporting the continued development of the VANADIS® platform.

    Previously, David held senior management positions at Procter & Gamble, Royal Sanders and Ferro, followed by executive and advisory roles supporting technology‑based companies in strategy, business development, corporate finance and organisational development.

  • Paul Quax, PhD

    • Professor of Experimental Vascular Medicine, LUMC

    • Fellow, American Heart Association (FAHA) & Established Investigator, Dutch Heart Foundation

    • Board member, Dutch Atherosclerosis Society; expert in vascular surgery & microvascular regeneration

  • Ioakim Spyridopoulos, MD, FRCP, FESC

    • Professor of Cardiology & Cardiovascular Gerontology, Newcastle University

    • Honorary Consultant Interventional Cardiologist, Freeman Hospital

    • Director, Cardio‑Immunology Lab, Translational & Clinical Research Institute

For more information, contact us.